The Jackson Laboratory provides the most widely published and cutting-edge models for oncology research and offers a comprehensive suite of solutions for your oncology research needs.
Over 400 patient-derived xenograft (PDX) tumors are available for engrafting into immunocompromised NSG™ mice for shipment to your facility or use in JAX-directed preclinical efficacy studies.
A robust immuno-oncology platform for efficacy testing of novel immunotherapies targeting T cells and myeloid cells.
I am interested in mammary tumors.
Jennifer Sargent and Mark Warner have won a major publication award, highlighting their work with PDX.
Improving cancer patient outcomes depends on expanding our understanding of basic cancer biology as well as improving...
I am currently engaged in the investigation of the impact of mesenchymal lineage cells and immune-regulatory myeloid cells on adaptive...
Jeff Chuang has summarized the power of 3D cell models and mapped out the key milestones required for implementation of...
In a new paper, Jennifer Trowbridge presents the factors and processes that contribute to Hematopoietic stem cells decline...
Trowbridge has been recognized as an outstanding early-career scientist and will receive a $750,000 award.
The development and providing of the cutting-edge Genome technologies methods for biomedical research.
JAX researchers reveal proteins from two families are consistently activated and likely play a role in promoting chronic inflammation with...